Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
medication
|
| gptkbp:activeDuring |
methylphenidate
|
| gptkbp:associatedWith |
improved academic performance
improved focus behavioral improvement reduced impulsivity |
| gptkbp:availableIn |
generic version
|
| gptkbp:availableSizes |
once daily
|
| gptkbp:brand |
gptkb:Concerta
gptkb:Ritalin Daytrana Metadate |
| gptkbp:clinicalTrials |
safety studies
ADHD treatment studies long-term efficacy studies |
| gptkbp:contraindication |
glaucoma
heart problems hyperthyroidism |
| gptkbp:dosageForm |
capsule
|
| gptkbp:drugInterdiction |
available online
|
| gptkbp:duration |
up to 8 hours
|
| gptkbp:endOfLife |
2 to 4 hours
|
| gptkbp:formFactor |
extended-release capsule
|
| gptkbp:gestationPeriod |
C
|
| gptkbp:hasPopulation |
children
adults adolescents |
| gptkbp:healthcare |
improved due to extended release
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ritalin LA
|
| gptkbp:inheritsFrom |
1 to 2 hours
|
| gptkbp:interactsWith |
gptkb:MAO_inhibitors
antidepressants blood pressure medications |
| gptkbp:lastProduced |
2005
|
| gptkbp:manufacturer |
Novartis
|
| gptkbp:marketedAs |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:United_States |
| gptkbp:packaging |
bottle
|
| gptkbp:providesSupportFor |
II
|
| gptkbp:route |
oral
|
| gptkbp:sideEffect |
headache
insomnia nervousness stomach pain loss of appetite |
| gptkbp:skills |
10 mg
20 mg 30 mg |
| gptkbp:usedFor |
Attention Deficit Hyperactivity Disorder (ADHD)
|